目的 探讨甘海胃康胶囊联合艾司奥美拉唑治疗胃溃疡的临床疗效。方法 选取2020年11月-2022年11月徐州医科大学附属连云港医院收治的124例胃溃疡患者，按照随机数字表法分为对照组和治疗组，每组各62例。对照组口服艾司奥美拉唑镁肠溶胶囊，20 mg/次，1次/d。治疗组在对照组治疗此基础上口服甘海胃康胶囊，6粒/次，3次/d。两组疗程均为6周。观察两组的临床疗效、幽门螺杆菌（Hp）根除率及溃疡愈合率。比较治疗前后两组典型表现评分、慢性病生命质量测定量表体系之消化溃疡量表第二版（QLICD-PU V2.0）评分及血清胃蛋白酶原Ⅰ与胃蛋白酶原Ⅱ比值（PGR）、胃泌素-17（G-17）、白细胞介素-6（IL-6）水平。结果 治疗后，治疗组总有效率是96.77%，较对照组的87.10%显著提高（P<0.05）。治疗后，两组胃脘疼痛、胃胀、反酸、嗳气评分及其总分均显著降低（P<0.05）；治疗后，治疗组典型表现评分降低更显著（P<0.05）。治疗后，两组QLICD-PU V2.0中共性模块、特异性模块评分及量表总分均显著增加（P<0.05）；治疗后，治疗组QLICD-PU V2.0评分高于对照组（P<0.05）。治疗组Hp根除率、溃疡愈合率分别为91.94%、75.81%，均显著高于对照组的79.03%、58.06%（P<0.05）。治疗后，两组血清PGR、G-17、IL-6水平均显著下降（P<0.05）；且治疗后，治疗组血清PGR、G-17、IL-6水平均显著低于对照组（P<0.05）。结论 甘海胃康胶囊联合艾司奥美拉唑治疗胃溃疡疗效较好，能有效促进患者典型表现的减轻、生命质量的提升及Hp根除和溃疡愈合，对胃黏膜功能恢复及炎症反应缓解具有较好的调控作用，值得临床推广应用。

Objective To explore the clinical efficacy of Ganhai Weikang Capsules combined with Esomeprazole Magnesium Enteric-coated Capsules in treatment of gastric ulcer. Methods A total of 124 patients with gastric ulcer admitted to Lianyungang Hospital Affiliated to Xuzhou Medical University from November 2020 to November 2022 were selected and divided into control group and treatment group according to random number table method, with 62 cases in each group. Patients in the control group were po administered with Esomeprazole Magnesium Enteric-coated Capsules, 20 mg/time, once daily. Patients in the treatment group were po administered with Ganhai Weikang Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy, Helicobacter pylori (Hp) eradication rate, and ulcer healing rate of two groups was evaluated. The typical performance score, the second version of the chronic disease quality of life scale (QLICD-PU V2.0) score, the ratio of serum pepsinogen I to pepsinogen II (PGR), gastrin-17 (G-17), and interleukin-6 (IL-6) levels were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 96.77%, which was significantly higher than that of the control group (87.10%) (P < 0.05). After treatment, the scores of epigastric pain, distension, acid reflux, belching and their total scores were significantly decreased in both groups (P < 0.05). After treatment, the typical performance score of the treatment group decreased more significantly (P < 0.05). After treatment, the scores of common modules, specific modules and total scores of QLICD-PU V2.0 in both groups were significantly increased (P < 0.05). After treatment, QLICD-PU V2.0 score in the treatment group was higher than that in the control group (P < 0.05). Hp eradication rate and ulcer healing rate in treatment group were 91.94% and 75.81%, respectively, which were significantly higher than 79.03% and 58.06% in control group (P < 0.05). After treatment, serum levels of PGR, G-17 and IL-6 were significantly decreased in both groups (P < 0.05). After treatment, the serum levels of PGR, G-17 and IL-6 in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Ganhai Weikang Capsules combined with esomeprazole has good curative effect in treatment of gastric ulcer, and can effectively promote the reduction of typical manifestations, improvement of life quality, eradication of Hp and the healing of ulcer, and has a good regulatory effect on recovery of gastric mucosa function and the relief of inflammatory response, which is worthy of clinical application.

R975

连云港市第一人民医院科研项目（SYSD2022-0163）